A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.

Trial Details

NCT ID
NCT07226427
Phase
PHASE1
Sponsor
Stemline Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • MEN2501
Locations (sample)
  • Springdale, Arkansas, United States|36.18674,-94.12881
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

  • Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube …
  • Key Exclusion Criteria:
  • Participants with primary platinum-refractory disease.
  • Note: Other protocol-defined inclusion/exclusion criteria may apply.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →